View source for Chemistry:Robatumumab

{{short description|Chemical compound}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464383074
| image = 
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = CD221
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 934235-44-6
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V983921H3B
| KEGG = D10056
| KEGG_Ref = {{keggcite|changed|kegg}}
<!-- Chemical data -->
| C=6418 | H=9960 | N=1732 | O=1992 | S=42
}}

'''Robatumumab''' (proposed INN; also known as '''SCH 717454''' and '''MK-7454''') is a [[Biology:Monoclonal antibody|monoclonal antibody]] and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.<ref>"robatumumab", p. 337 in: {{cite journal |url=https://www.who.int/medicines/publications/druginformation/innlists/PL100.pdf
|title=Proposed International Nonproprietary Names: List 100 |pages=311–67 |journal=WHO Drug Information |volume=22 |issue=4 |year=2008 |author=Quality Assurance and Safety of Medicines | veditors = Encrenaz C }}</ref>

Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.<ref>{{cite journal | vauthors = Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D | display-authors = 6 | title = A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma | journal = Pediatric Blood & Cancer | volume = 63 | issue = 10 | pages = 1761–70 | date = October 2016 | pmid = 27362300 | pmc = 5129487 | doi = 10.1002/pbc.26087 }}</ref><ref>{{ClinicalTrialsGov|NCT00551213|A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)}}</ref> Merck has since discontinued development.<ref>{{cite web | title = Robatumumab | url = http://adisinsight.springer.com/drugs/800027277 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}</ref>

== References ==
{{reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental cancer drugs]]


{{Sourceattribution|Robatumumab}}